biotech news today obesity drugs glp-1 The race may have a new contender. 👋 Regeneron reported Phase 3 data showing its drug candidate delivered up to 19.3% weight loss at 48 weeks, approaching the efficacy seen ADA '26: Lilly's dominance, Pfizer's

For patients with pre-existing mild or moderate DR, the effects of GLP-1 drugs could significantly worsen this condition

GLP-1 Drug Prescriptions Have Doubled in Recent Years, But Many Users Quit Soon After Starting Use of Ozempic, Wegovy, Mounjaro and other GLP-1 drugs has spiked in recent years due to their effectiveness promoting weight loss, but side effects often cause users to discontinue the treatment within the first year

Effects on liver Despite the lack of expression of GIPR (41, 191) and GLP-1R (192, 193) in hepatocytes, both GIP and GLP-1 have indirect effects on hepatic lipid and glucose metabolism (194)

The risk-benefit calculation for semaglutide remains favorable for most patients with obesity or type 2 diabetes, conditions that carry their own serious long-term health risks